Herrmann W, Biermann J, Ratzmann K P, Lindhofer H G
Zentrallabor des Bezirkskrankenhauses Meiningen, Berlin.
Med Klin (Munich). 1992 Jan 15;87(1):12-5.
Non-insulin-dependent diabetes mellitus (NIDDM) is associated with increased very-low-density lipoprotein (VLDL) and triglyceride concentrations as abnormalities of low-density lipoprotein (LDL) composition. Because fish oil has a strong triglyceride lowering effect in case of normolipemic subjects, we investigated the influence of supplementary fish oil diet in patients suffering from NIDDM (n = 19), who until now were not treated by drugs but only by diet. The study was started with a placebo-run-in-period for four weeks (phase I, 6 g rape seed oil capsules/d), followed by a verum period for twelve weeks (phase II, 6 g fish oil concentrate capsules/d), and a wash-out-period for four weeks (phase III, 6 g rape seed oil capsules/d). The fish oil supplementation contained at least 3 g eicosapentenoic and docosahexenoic acid. The lipoproteins, apolipoproteins, blood glucose, and insulin level (fasting and after load test) were checked at the beginning and at the end of each phase. In comparison to the placebo rape seed oil supplementation, the fish oil diet effected a decrease of serum triglycerides by 29%. LDL-cholesterol increased by 9%, HDL-cholesterol by 9% (especially HDL2-cholesterol), and apolipoprotein B by 4%. Apolipoprotein A-I was reduced by 9%. The fasting blood glucose and the glucose load test as the insulin level (fasting and after load test) showed no significant changes at the end of the verum period in comparison to the run-in-phase.(ABSTRACT TRUNCATED AT 250 WORDS)
非胰岛素依赖型糖尿病(NIDDM)与极低密度脂蛋白(VLDL)增加及甘油三酯浓度升高有关,后者为低密度脂蛋白(LDL)组成异常。由于鱼油对血脂正常的受试者有很强的降低甘油三酯作用,我们研究了补充鱼油饮食对NIDDM患者(n = 19)的影响,这些患者此前未接受药物治疗,仅采用饮食控制。研究开始时进行为期四周的安慰剂导入期(第一阶段,6克菜籽油胶囊/天),随后是为期十二周的真药期(第二阶段,6克浓缩鱼油胶囊/天),以及为期四周的洗脱期(第三阶段,6克菜籽油胶囊/天)。补充的鱼油至少含有3克二十碳五烯酸和二十二碳六烯酸。在每个阶段开始和结束时检查脂蛋白、载脂蛋白、血糖和胰岛素水平(空腹及负荷试验后)。与补充安慰剂菜籽油相比,鱼油饮食使血清甘油三酯降低了29%。低密度脂蛋白胆固醇升高了9%,高密度脂蛋白胆固醇升高了9%(尤其是高密度脂蛋白2胆固醇),载脂蛋白B升高了4%。载脂蛋白A-I降低了9%。与导入期相比,真药期结束时空腹血糖、葡萄糖负荷试验及胰岛素水平(空腹及负荷试验后)均无显著变化。(摘要截选至250词)